
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc. is positioned for strong financial growth, with an increased peak revenue estimate of $6.8 billion by 2040, reflecting potential market expansion for its pneumococcal conjugate vaccine (PCV) amid anticipated regulatory support and a universal recommendation for adults over 50. The company's clinical advancements, particularly with the VAX-31 product candidate, demonstrate promising efficacy, as evidenced by its successful Phase 3 results and superior performance compared to existing vaccines, which could attract heightened investor interest in upcoming trial readouts. Furthermore, the strategic adjustments to the VAX-31 trial aimed at enhancing the probabilities of positive outcomes reinforce the firm’s outlook, suggesting a potential for continued stock performance appreciation in the coming years.
Bears say
Vaxcyte Inc. faces significant downside risks primarily stemming from potential delays and setbacks in its research and development, regulatory approvals, and commercial uptake, which could hinder the advancement of its vaccine candidates. The recent underwhelming readout from the VAX-24 Phase 2 trial has contributed to investor skepticism, compounded by the overall market's challenging environment for vaccine stocks due to increased regulatory scrutiny. Additionally, even if Vaxcyte's vaccines achieve clinical success, there remains a risk that they may not be endorsed by national vaccine guidelines, severely limiting their commercial viability.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares